证券代码：600196 证券简称：复星医药 公告编号：2025-153 上海复星医药（集团）股份有限公司 ● 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统（A股股东适用） ● 拟出席本次股东会的H股股东的参会事项，请参见2025年9月29日本公司于香港联合交易所有限公司 网站（https://www.hkexnews.hk）以及本公司网站（https://www.fosunpharma.com）发布的有关2025年第 一次临时股东会的通告、通函、代表委任表格等文件。 一、召开会议的基本情况 （一）股东会类型和届次：2025年第一次临时股东会（以下简称"本次股东会"或"本次会议"） （二）股东会召集人：董事会 （三）A股股东投票方式：采用现场投票和网络投票相结合的方式 （四）现场会议召开的日期、时间和地点 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 股东会召开日期：2025年10月23日 召开的日期时间：2025年10月23日 13点30分 召开 ...

Core Viewpoint - The company has established a long-term incentive mechanism to ensure the successful implementation of the 2025 A-share option plan, aiming to enhance management performance and maximize shareholder interests [1][2]. Group 1: Assessment Objectives and Principles - The purpose of the assessment is to improve corporate governance and establish a long-term incentive mechanism to ensure the achievement of the company's strategic and operational goals by 2025 [1]. - The assessment must adhere to principles of fairness, openness, and impartiality, linking the A-share option plan closely with the performance and contributions of the incentivized individuals [1][2]. Group 2: Assessment Scope and Organization - The assessment applies to all individuals participating in the 2025 A-share option plan [1]. - The company's Board of Directors' Compensation and Assessment Committee will lead and organize the assessment work [1]. Group 3: Assessment Indicators and Standards - The assessment will evaluate the company's financial performance indicators annually, focusing on "net profit attributable to shareholders" and "revenue from innovative drugs" [1][2]. - Specific targets for the assessment indicators include a net profit target of 33.2 billion RMB for the first year, increasing to 39.6 billion RMB and 47.7 billion RMB in subsequent years [2][3]. Group 4: Assessment Period and Frequency - The assessment period spans from 2025 to 2027, with evaluations conducted annually [3][4]. Group 5: Assessment Procedures and Results Management - The Human Resources Department, under the guidance of the Compensation and Assessment Committee, is responsible for the assessment process and maintaining the results [4]. - Incentivized individuals have the right to understand their assessment results and can appeal if they disagree with the evaluations, following the established procedures [4].